Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Cyclacel presents an update on clinical development programs

Nov. 29, 2007

New agents with potential in the treatment of cancer disclosed in recent patent literature

Nov. 29, 2007

E.U. approves Tasigna for Ph+ CML patients with poor response to current therapy

Nov. 28, 2007

Kinex initiates phase I clinical trial of KX2-391 for advanced solid tumors and lymphoma

Nov. 28, 2007

Cleveland BioLabs initiates phase II trial of Curaxin for advanced renal cell carcinoma

Nov. 28, 2007

EMEA accepts for technical review MAA submission by Introgen for Advexin

Nov. 28, 2007

VioQuest initiates phase IIa study of Lenocta for the treatment of solid tumors

Nov. 27, 2007

Merck & Co. files marketing authorization application with EMEA for vorinostat

Nov. 27, 2007

European Commission approves Wyeth Pharmaceuticals' Torisel for renal cell carcinoma

Nov. 27, 2007

Selective and multitargeted B-Raf inhibitors described at Deciphera

Nov. 27, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...